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Abstract
Objective—Salsalate treatment has well-known effects on improving glycemia and the objective 
of this study was to examine whether the mechanism of this effect is related to changes in adipose 
tissue.
Methods—We conducted a randomized double-blind and placebo-controlled trial in obese 
Hispanics (18-35 years). The intervention consisted of 4 g/day of salsalate (n=11) versus placebo 
(n=13) for 4 weeks. Outcome measures included glycemia, adiposity, ectopic fat, and adipose 
tissue gene expression and inflammation.
Results—In those receiving salsalate, plasma fasting glucose decreased by 3.4% (P<0.01), free 
fatty acids decreased by 42.5% (P=0.06) and adiponectin increased by 27.7% (P<0.01). Salsalate 
increased insulin AUC by 38% (P=0.01) and HOMA-B by 47.2% (P<0.01) while estimates of 
insulin sensitivity/resistance were unaffected. These metabolic improvements occurred without 
changes in total, abdominal, visceral, or liver fat. Plasma markers of inflammation/immune 
activation were unchanged following salsalate. Salsalate had no effects on adipose tissue including 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Michael Goran, PhD University of Southern California Department of Preventive Medicine Childhood 
Obesity Research Center 2250 Alcazar Street, CSC 200 Los Angeles, CA 90033 Phone: 323-442-3027 Fax: 323-442-4103 
goran@usc.edu. 
Disclosure Statement: The authors have nothing to disclose.
HHS Public Access
Author manuscript
Obesity (Silver Spring). Author manuscript; available in PMC 2016 March 01.
Published in final edited form as:
Obesity (Silver Spring). 2015 March ; 23(3): 543–551. doi:10.1002/oby.20991.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
adipocyte size, presence of crown-like structures, or gene expression of adipokines, immune cell 
markers, or cytokines downstream of NF-κB with the exception of downregulation of IL-1β 
(P<0.01).
Conclusions—Our findings suggest that metabolic improvements in response to salsalate 
occurred without alterations in adiposity, ectopic fat, or adipose tissue gene expression and 
inflammation.
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Introduction
Obesity is often associated with chronic low-grade inflammation, which increases the risk 
for insulin resistance, metabolic complications, and type 2 diabetes (1-4). Evidence suggests 
that adipose tissue is a significant contributor to this inflammatory state (5-8). Treatment 
strategies have included anti-inflammatory therapies to improve metabolic health. In 
rodents, salicylates inhibit obesity-induced inflammation and improve insulin resistance (9, 
10). Recent clinical investigations have shown that salsalate (a prodrug of salicylate) 
favorable affects glycemia in predominantly obese Caucasian adults with impaired fasting 
glucose (IFG), impaired glucose tolerance (IGT), and/or type 2 diabetes (11-14). In general, 
results from these studies have shown that salsalate improved glucose and lipid homeostasis 
(11-14). Further, salsalate has been shown to inhibit systemic inflammation and NF-κB 
activity in peripheral blood mononuclear cells (11) and adipose tissue (14). Collectively, 
these findings suggest that salsalate-induced metabolic improvements may be mediated by 
changes in adipose tissue, especially decreases in inflammation.
These clinical outcomes are particularly important since salsalate is an inexpensive 
treatment that could be used for prevention or reversal of cardiometabolic abnormalities 
occurring during obesity. Yet, there is limited data about the utility of salsalate to improve 
metabolic health in persons without type 2 diabetes (15-18) and its effects on adipose tissue 
inflammation are uncertain. Furthermore, treatment with salsalate has not be evaluated 
exclusively in Hispanics, who suffer from a greater prevalence of obesity (19) and metabolic 
disease risk than non-Hispanic whites (20). We therefore conducted a randomized, double-
blind and placebo-controlled trial of salsalate in obese Hispanic young adults without type 2 
diabetes to determine whether the known effects of salsalate on improving glycemic is 1) 
applicable to obese Hispanics without type 2 diabetes and 2) mediated by potential effects of 
salsalate on adipose tissue.
Methods
Study Design
The study was a 4-week, randomized double-blind and placebo-controlled investigation, 
which compared 4 g/day of salsalate (2 g twice daily) with matching placebo (Merical, 
Anaheim, CA, USC). Previous studies demonstrating safety, tolerability, metabolic benefits 
as well as the anti-inflammatory effects of salsalate were used to direct our treatment dosage 
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and duration (11-14). Primary outcomes included effects on glycemia, insulin resistance, 
and markers of systemic and adipose tissue inflammation. The protocol specified stepped 
reductions of 500 mg/day for symptoms related to salicylate (e.g., tinnitus). Pills were 
counted at the end of the 4 weeks and participants were called weekly to encourage 
adherence and inquire about potential adverse events. Participants were instructed to 
maintain their current activity and dietary patterns during the study.
Participants and Screening
Participants signed an informed consent approved by the University of Southern California’s 
(USC) Institutional Review Board prior to undergoing study measurements or interventions. 
Inclusion criteria required that participants be otherwise healthy obese (body mass index 
[BMI] ≥30 kg/m2) Hispanic adults 18-35 years of age. Hispanic ethnicity required that both 
parents and grandparents be of Hispanic descent (by self-report). Participants were excluded 
if they had diabetes, peptic ulcer disease, history of gastrointestinal bleeding, blood clotting 
disorder, liver or kidney function abnormalities, asthma, allergy to non-steroidal anti-
inflammatory drugs (NSAIDs), or were pregnant or lactating. Participants were excluded if 
they were taking any medications that could affect body composition, metabolism or 
inflammation (e.g., thyroid replacement, β-blockers, NSAIDs, statins). Although not 
included as exclusion criteria, none of the participants reported using dietary supplements 
(including anti-inflammatory omega-3). In the last year of the study, those enrolled had at 
least two of the latter; HOMA-IR ≥3.5, elevated HbA1C (5.7-6.4% or 38.8-46.4 mmol/mol), 
or elevated erythrocyte sedimentation rate (≥15 mm/hr). Criteria were used to increase the 
proportion of participants expected to have abdominal fat inflammation. Those enrolled 
based on these criteria were equally represented in both groups. All participants included in 
this study had adipose tissue biopsies at baseline and post-test.
2-Hour OGTT
A 2-hour OGTT was performed after an overnight fast at baseline and immediately 
following the last treatment dose. Blood samples were collected at baseline and 15, 30, 45, 
60, and 120 minutes following ingestion of glucose (75 g). HOMA-IR, an index of insulin 
resistance, was calculated as fasting glucose (mg/dL) × insulin (μU/mL) / 205. HOMA-B, an 
indirect measure of β-cell function, was calculated as fasting insulin (μU/mL) × 360 / 
[fasting glucose (mg/dL) − 63]. QUICKI, an index for insulin sensitivity, was calculated as 
1 / (log (fasting insulin (μU/mL)) + log (fasting glucose (mg/dL))) (21). Finally, the Matsuda 
Index, an indirect but more robust estimate of insulin sensitivity, was calculated as 10,000 / 
sqrt [(fasting glucose (mg/dL) × fasting insulin (μU/mL)) × (mean glucose × mean insulin 
during the OGTT)]. Glucose, insulin, and C-peptide area under the curve (AUC) were 
calculated from the OGTT data. Dietary intake and weekly activity were assessed using 24-
hour diet recalls (22) and Godin-Shephard Leisure-Time Physical Activity questionnaires 
(23) before and after treatment. Nutrition data were analyzed using the Nutrition Data 
System for Research (version 2012) developed at the University of Minnesota.
Assays
Assays were performed in duplicate (except glucose and C-peptide) at the USC Metabolic 
Assay Core and had coefficients of variation of less than fifteen percent. Glucose was 
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assayed on a Yellow Springs 2710 Analyzer (Yellow Springs, OH) using the glucose 
oxidase method. Insulin was assayed using a specific human ELISA kit from EMD 
Millipore (St. Charles, MO) and fasting free fatty acids (FFA) were quantified using a 
colorimetric kit (NEFA-HR(2)) from Wako Diagnostics (Richmond, VA). C-peptide was 
assayed by an automated enzyme immunoassay (Tosoh Bioscience Inc., AIA 600 II 
analyzer, South San Francisco, CA). Circulating cytokines and markers of immune 
activation, including high sensitivity interleukin-6 (hsIL-6), soluble tumor necrosis receptor-
II (sTNFrII), sCD14 (24), and sCD163 (25) were measured by human ELISA from R&D 
Systems Inc. (Minneapolis, MN). Adipokines, including adipsin and adiponectin, were 
assayed using human ELISA from R&D Systems Inc. (Minneapolis, MN) and EMD 
Millipore (St. Charles, MO). Complete blood counts and comprehensive chemistry panels 
were performed by the USC Clinical Laboratory.
Adipose Tissue Biopsies
Baseline and post-test subcutaneous abdominal adipose tissue biopsies were obtained in the 
right anterior axillary line at the level of the umbilicus using a 6-mm Bergström side-cutting 
needle (Micrins Surgical, Inc; Lake Forest, IL). Adipose tissue was rapidly irrigated with 
iced saline and immediately transported for flow cytometry, fixed for 
immunohistochemistry, or flash frozen in liquid nitrogen for subsequent whole-tissue 
Fluidigm gene expression. To quantify immune cells in adipose tissue we used flow 
cytometry and gated for live cells, leukocytes (CD45+), and then monocytes and 
macrophages (CD45+/CD14+). The percent of monocytes and macrophages was calculated 
as the difference between the percent of CD45+/CD14+ cells and the percent of CD45+/
CD14− isotype control cells. For immunohistochemistry, adipose tissue samples were 
formalin-fixed and paraffin-embedded. Four consecutive, 5-micron sections of adipose 
tissue were stained with hematoxylin-eosin and CD68 antibody (Leica Biosystems, 
Newcastle, UK) to examine crown-like structures (CLS) as a marker of adipose tissue 
inflammation. Since CLS were not overly abundant, a single blinded technician examined 
all sections for the presence or absence of macrophage CLS (6, 26). Four independent fields 
at 20x magnification were captured from the first mounted section on each slide for cell 
sizing. Adipose cell size (μ2) was obtained from each field captured using Fiji quantitative 
microscopy software (27). The Genoseq Core at the University of California Los Angeles 
performed adipose tissue gene expression assays using Fludigm DELTAgene assays. Gene 
expression from the post-test biopsy was compared to baseline in order to calculate fold 
change (FC). Assays included genes involved in adipose tissue inflammation (inflammatory 
cytokines and immune cell markers) as well as insulin, FFA, and lipopolysaccharide (LPS) / 
Toll-like receptor (TLR) signaling.
Adiposity
A DEXA scan was used to control for possible changes in body composition (e.g., percent 
body fat and lean tissue mass) before and after the 4-week intervention. At baseline and 
within one week of completing the intervention, a whole abdominal (top of liver to iliac 
crest) 3-Tesla magnetic resonance imaging (MRI) scan (Excite HD; GE Healthcare, 
Waukesha, Wisconsin) was used to measure subcutaneous abdominal adipose tissue 
(SAAT), visceral adipose tissue (VAT), liver fat fraction, and pancreatic fat fraction as 
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previously reported (28). The MRI utilized the IDEAL method (GE Healthcare), which 
separates water and fat components using chemical-shift MRI. Fat fraction was calculated as 
the fat components divided by the sum of the fat and water components (28, 29). This 3-D 
whole abdominal MRI scan provides SAAT and VAT in liters as well as liver and pancreatic 
fat as the percentage of fat found within each organ tissue. A single analyst performed all 
MRI image post-processing, tissue segmentation, and analysis using SliceOmatic software 
(Tomovision, Inc., Montreal, Québec, Canada).
Statistical Analysis
Study data were managed using Research Electronic Data Capture (REDCap) tools hosted at 
the USC (30). Statistical analyses were performed with IBM SPSS Statistics (version 21). 
Data are reported as median (25th, 75th percentile) or median percent change unless 
otherwise noted. Paired comparisons (post-test versus baseline) and unpaired group 
comparisons were performed by the Mann-Whitney U Test on medians or the McNemar’s 
test and Fisher’s Exact test for CLS data. The effect of salsalate (Ptreatment) was examined 
using analysis of covariance (ANCOVA) where the dependent variable was the change from 
baseline in each variable of interest (e.g., plasma markers of metabolic health and adipose 
tissue biopsy outcomes). These models controlled for the baseline measure of each 
dependent variable and baseline percent body fat. Change in CLS (presence or absence) was 
examined using Fisher’s Exact test as well as logistic regression including the same 
covariates. When necessary, log transformations were performed to meet assumptions of 
normality. Results were considered significant when two-sided P-value was less than 0.05.
Results
Baseline Assessments
Thirty participants were randomized to the study and 25 completed the intervention (Figure 
1). Table 1 lists the baseline characteristics of the 24 participants with complete paired study 
data. On average, participants were approximately 20 years old and 58% were male. Those 
in the placebo and salsalate group did not significantly differ in any parameter except fasting 
insulin and estimates of insulin sensitivity, resistance and secretion. The salsalate group had 
a higher fasting insulin [11.0(9.5, 13.5) vs. 7.2(5.0, 10.2) μU/mL, P=0.02] fasting insulin to 
C-peptide ratio [3.3(3.0, 3.8) vs. 2.8(2.5, 3.4), P=0.03], HOMA-IR [2.2(2.0, 2.8) vs. 1.5(1.0, 
2.3), P=0.03], and lower QUICKI [0.34(0.33, 0.34) vs. 0.36(0.34, 0.34), P=0.03] and 
Matsuda Index [1.9(1.4, 2.1) vs. 2.7(2.0, 3.8), P=0.01].
Participation and Compliance
Two participants in the placebo and three in the salsalate arm dropped out of the study. The 
reasons included lack of time, loss of interest, or illness / injury that was unrelated to study 
participation. There were four instances of tinnitus (placebo n=1 and salsalate n=3) that were 
graded mild to moderate, resolved within 1-2 weeks during continued treatment, and did not 
require a dose reduction. Changes in weight, blood pressure (BP), liver function tests, blood 
urea nitrogen, serum creatinine, and estimated glomerular filtration rate did not change with 
salsalate treatment or vary by treatment groups (data not shown). At the end of the study, 
there were no differences in the number of untaken pills in the placebo group compared to 
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salsalate treatment [19.0(53.0) vs. 22.5(32.0) pills, P=0.73]. As shown in Table 2, BMI, total 
body fat percent, SAAT, VAT, liver, and pancreatic fat did not change within or between 
treatment groups. Finally, upper and lower body fat percent, lean tissue mass, total energy 
intake, macronutrients (protein, fat, fiber, and carbohydrates), and leisure activity did not 
differ between the groups at baseline or change within or between treatment groups (data not 
shown).
Fasting Measures and OGTT Results
Table 2 shows outcome variables before and after the 4-week treatment intervention. There 
were treatment related differences in fasting blood glucose levels (Ptreatment<0.01) where the 
median blood glucose decreased 3.4% (P<0.01), with a median reduction of 2.9 mg/dL in 
the salsalate group but not placebo group (Figure 2A). Salsalate resulted in lower fasting 
FFA (Ptreatment=0.02), where the median blood FFA levels decreased in the salsalate 
(−42.5%, P=0.06, respectively) but not in the placebo group (Figure 2C). Salsalate resulted 
in higher insulin AUC (Ptreatment<0.01), where the median value increased in the salsalate 
(+38.0%, P=0.01) but not placebo group (Figure 3C-D). Although there was a trend for an 
increased fasting C-peptide in the placebo group (Ptreatment=0.05), salsalate treatment did not 
significantly alter levels of fasting insulin and fasting C-peptide (Figure 2B-C) or glucose 
AUC and C-peptide AUC (Figure 3A-B and E-F). Fasting insulin to C-peptide ratios were 
increased in the salsalate but not placebo group (+57.6%, P<0.01; Ptreatment<0.01). 
Treatment with salsalate did not alter estimates of insulin sensitivity or resistance (QUICKI, 
HOMA-IR or Matsuda Index) while a proxy for β-cell function (HOMA-B) increased in the 
salsalate (+47.2%, P<0.01; Ptreatment<0.01) but not placebo group.
Adipokines and Markers of Inflammation
Salsalate treatment resulted in higher plasma adiponectin levels (27.7%, P<0.01; 
Ptreatment<0.001) with no change in the placebo group (Table 2). Circulating adipsin, 
cytokines, and markers of immune activation, including hsIL-6, sCD14, and sCD163, were 
unchanged within each group and there was no effect of salsalate treatment. Although there 
was a trend towards decreased sTNFrII levels in the salsalate group (−5.2%, p=0.09), there 
were no treatment related differences. From the fat biopsies, treatment did not alter the 
average fat cell size (Ptreatment=0.90) or presence of CLS (Ptreatment=0.40), yet there was a 
modest decrease in the average fat cell size among those in the placebo group (P=0.046). To 
examine adipose tissue inflammation in a more quantitative manner, the percent leukocytes 
and monocytes/macrophages in each fat sample were assessed using flow cytometry. 
Overall, there were no within group or treatment related differences in these immune cell 
populations. Despite systemic metabolic improvements in glycemia, FFA, and adiponectin 
levels, there were no within group or treatment related differences in adipose tissue gene 
expression for adiponectin, dipeptidyl peptidase-4 (DPP4), leptin, adipsin or any signaling 
pathways of interest (i.e., insulin, FFA, LPS/TLR). Further, there were no significant 
changes in gene expression of immune cell markers, including ACP5, CD68, CD163, 
MCP1, FOXP3, and LIPA within or between treatment groups (Supplemental Table 1). Of 
several inflammatory gene markers affected by NF-κB (e.g., IL-6, IL-8, IL-1R, TNFα, 
NOS, ICAM1, VCAM1), salsalate treatment was only associated with a 47% decreased IL1-
β expression (P=0.002) while there was no change in the placebo group (Ptreatment=0.29).
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Discussion
In this study of obese non-diabetic Hispanics, who are at increased risk for metabolic disease 
(20), we found that salsalate improved fasting glucose, insulin, and FFA levels as shown in 
prior studies in Caucasians. Previous studies suggest that these metabolic improvements are 
due to salsalate based suppression of inflammation, presumed to originate from abdominal 
fat (11, 31, 32). For this reason, we examined whether salsalate treatment had similar effects 
in non-diabetic obese Hispanics and whether any changes were accompanied by changes in 
adiposity, fat distribution, ectopic fat, adipose tissue gene expression, or attenuation of 
adipose tissue inflammation. Overall, we found that median blood glucose levels decreased 
by 2.9 mg/dL following salsalate treatment, even though ~88% of participants had baseline 
blood glucose levels within the normal range (≤100 mg/dL). Salsalate treatment also 
reduced fasting FFA by 42.5% and increased plasma adiponectin by 27.7%. Unique to this 
study, we show that each of these changes occurred without alterations in adipose tissue, 
including adiposity, fat distribution, ectopic fat, adipocyte size, and adipose tissue gene 
expression of adipokines and markers of adipose tissue inflammation.
Using histology, flow cytometry, and gene expression, we found that salsalate did not affect 
markers of adipose tissue inflammation, including the presence of CLS or the percent of 
immune cells (monocytes/macrophages and leukocytes) in biopsy specimens. Furthermore, 
we did not detect changes in expression of immune cell markers or IL-6, IL-8, IL1R, TNFα, 
NOS, ICAM1, and VCAM1, which is consistent with another report (14). We did observe a 
significant decrease in IL-1β gene expression after salsalate. Macrophage derived IL-1β 
stimulates IL-17 and IL-22 producing T cells (33), which are found in adipose tissue of 
insulin resistance individuals (7). Therefore, it is possible that salsalate exerted some of its 
metabolic effects through inhibition of macrophage derived IL-1β. However, given that 
other markers of adipose tissue inflammation were unchanged, it is unlikely that decreased 
IL-1β gene expression accounted for the improvements observed in fasting glucose and 
FFA.
Similar to previous salsalate studies, adiponectin levels significantly increased following 
treatment in non-diabetic obese Hispanics. Adiponectin has been shown to stimulate insulin 
sensitivity and modulate hepatic glucose production, fatty acid oxidation, and lipid synthesis 
(34-36), suggesting that metabolic improvements could relate to increases in this 
adiopokine. The marginal reduction in plasma sTNFrII following salsalate (P=0.09) 
indicates that increased adiponectin may contribute to reduced fasting glucose and FFA by 
decreasing systemic inflammation (35). However, we did not detect changes in other plasma 
markers of inflammation (hsIL-6, sTNFrII) or immune activation (sCD14, sCD163). 
Additionally, although adiponectin is exclusively produced by adipocytes, there were no 
changes in adipose tissue gene expression of adiponectin following treatment. Thus, results 
from our study suggest that increased circulating adiponectin levels did not result from 
salsalate-induced increases in adipocyte gene expression (37), but were due to either 
enhanced protein translation and secretion or decreased clearance by the liver or kidneys 
(35). These findings further indicate that salsalate does not alter adipose tissue; however, a 
recent study using fully differentiated human adipocytes found that salsalate increased 
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adiponectin mRNA levels through decreased expression of 11β-hydroxysteroid 
dehydrogenase type 1 (37).
Since salsalate did not alter adipose tissue inflammation or adipose tissue gene expression of 
adiponectin, we explored whether metabolic improvements were related to changes in the 
liver. High-dose aspirin (a primary metabolite of salsalate) therapy has been shown to 
improve hepatic insulin sensitivity, glucose production, and inflammation (38). Therefore, 
salsalate may have decreased fasting glucose and fasting FFA through hepatic alterations or 
decreased rates of insulin clearance. Supporting this, in Sprague-Dawley rats, salsalate has 
been shown to ameliorate hepatic steatosis through decreased fetuin-A expression via the 
AMPK-NF-κB dependent pathway (36). Using whole abdominal MRI imaging, we found 
that metabolic improvements occurred without reductions in liver fat. However, it is 
possible that this methodology was not sensitive enough to capture small alterations in 
hepatocyte lipid content, which could affect metabolism. Instead, changes in liver 
inflammation, and not declines in hepatic fat, may contribute to metabolic improvements 
seen in humans treated with salsalate. For example, unmeasured changes in insulin clearance 
by the liver could contribute to hyperinsulinemia, decreased hepatic glucose production, 
increased glucose and FFA uptake by peripheral tissues, and decreased adipose tissue 
lipolysis. Supporting this, in the current study we found that metabolic improvements were 
accompanied by increased insulin concentrations during the OGTT and increased HOMA-B, 
which appeared to be related to decreased insulin clearance as reported previously (11, 14, 
16, 18, 39).
There were several study limitations. Since race/ethnicity was based on self-report, future 
studies should verify these findings in a larger population with more definitive measures of 
ethnicity. Although participants were randomly assigned to placebo or salsalate, those in the 
salsalate group had somewhat higher baseline fasting insulin levels, were less insulin 
sensitive, and showed lower rates of insulin clearance than those in the placebo group. These 
differences likely resulted from the relatively small number of study participants. 
Notwithstanding, all findings were corrected for these baseline differences. This study 
examined non-diabetic obese Hispanics who had relatively normal fasting insulin levels and 
metabolic indices at baseline, perhaps accounting for why we did no observe improvements 
in insulin sensitivity or resistance (QUICKI, HOMA-IR, Matsuda Indices) following 
salsalate (40). Nonetheless, these findings are consistent with previous studies among those 
with insulin resistance and type 2 diabetes (13-15). Although there were no changes in the 
percent of immune cells or the proportion of those with CLS in adipose tissue, it is possible 
that there were changes in the proportion of pro- and anti-inflammatory macrophage 
subtypes that went undetected by our measures of adipose tissue inflammation. Despite 
these limitations, participants appeared to be adherent to all aspects of the protocol, which 
strengthens the treatment results. Pill counts indicated good adherence over the 4-week 
treatment period. The fact that there were no changes in diet, exercise, body fat percent, or 
ectopic fat provide further evidence that our findings can not be attributed to changes in 
lifestyle or adiposity. Thus, the metabolic improvements in our Hispanic participants were 
likely due solely to salsalate.
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In conclusion, 4 weeks of salsalate treatment lowered fasting glucose and FFA levels and 
increased adiponectin levels among non-diabetic obese Hispanic young adults, findings that 
are consistent with prior observations in Caucasians (11-14). To our knowledge, this is the 
first study to systematically examine the metabolic effects of salsalate as they related to 
adiposity, ectopic fat, and various markers of adipose tissue inflammation. Similar to 
previous studies, we demonstrated that salsalate treatment improved metabolic outcomes 
and add to the existing literature by showing that these changes occurred without alterations 
to percent body fat, volume of abdominal adipose tissue depots, liver fat, adipose tissue gene 
expression of important adipokines (adiponectin, adipsin, leptin), or adipose tissue 
inflammation. Based on our findings, future studies should examine how salsalate affects the 
liver, particularly hepatic insulin sensitivity and glucose production, as well as its effects on 
insulin and adiponectin clearance.
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What is already known about this subject
• Salsalate favorably affects glycemia and lipid homeostasis in studies among 
predominantly obese Caucasian adults with impaired fasting glucose, impaired 
glucose tolerance, and/or type 2 diabetes.
• Salsalate lowers fasting glucose in populations with relatively normal glucose 
levels where one study found beneficial effects in a predominantly Native 
American population.
• Salsalate inhibits systemic inflammation possibly through decreased NF-κB 
activity in peripheral blood mononuclear cells and adipose tissue.
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What this study adds
• Salsalate improves metabolic outcomes in obese Hispanics without type 2 
diabetes, a population that suffers from a greater prevalence of obesity and 
metabolic disease risk.
• Salsalate treatment does not alter adipose tissue, including adiposity, volume of 
abdominal adipose tissue depots, or liver fat.
• Metabolic improvements are not accompanied by attenuation of adipose tissue 
inflammation or changes in adipose tissue gene expression of important 
adipokines (e.g., adiponectin, leptin).
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Figure 1. Study Flow Diagram
Of those who completed the screening visit (n = 54), 18 were deemed ineligible, 5 lost 
contact, and 1 lost interest. *Reasons for ineligibility after screening included smoking (n = 
1), pregnancy (n = 1), abnormal routine blood chemistry results (n = 1), low BMI (n = 3), or 
exclusion based on HOMA-IR, HbA1C, and ESR (n = 12). Of the 30 randomized (15 
salsalate / 15 placebo), only 5 dropped. Reasons for dropout included lack of time (n = 2), 
loss of interest (n = 1), unrelated study illness (n = 1), and unrelated study injury (n = 1). 
♮Cold symptoms, including nausea, were unrelated to the intervention. #Injury involved a 
fractured rib that was unrelated to study involvement. **One participant did not have 
complete fat biopsy data and was not included in the analysis.
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Figure 2. Fasting Measures From the 2-hr OGTT
Fasting glucose (A), insulin (B), C-peptide (C), and free fatty acids (D) levels from the 2-hr 
OGTT. Individual participant data where black circles = salsalate groups and white circles = 
placebo. Treatment P-values are from ANCOVA, which controlled for the baseline 
dependent variable and body fat percent. Within group P-values correspond to Related-
Samples Wilcoxon Signed Rank Test. For visual representation, P-vales are only shown for 
P≤0.06.
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Figure 3. Glucose, Insulin, C-Peptide During the 2-hr OGTT
Results from the 2-hour OGTT. Mean ± standard deviation for plasma glucose (A, B), 
insulin (C, D), and C-Peptide (E, F) responses are shown for salsalate (left column) and 
placebo (right column). White circles and dashed lines = baseline. Back circles and solid 
lines = post-test. ΔMedian is equal to the difference between post-test and baseline AUC 
medians. *P<0.05, τP<0.01. P-values were obtained using ANCOVA analysis (change in 
salsalate vs. change placebo) with adjustment for the dependent variable at baseline as well 
as percent body fat. A significant treatment effect was only observed for insulin AUC 
(Ptreatment<0.01).
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Table 1
Baseline Characteristics of Participants at Study Enrollment
Salsalate
N=11
Placebo
N=13
General Characteristics
Age (years) 22.0 (19.0, 27.0) 19.0 (18.0, 25.5)
Sex (M/F) 6/5 8/5
Height (m) 1.7 (1.6, 1.8) 1.7 (1.6, 1.7)
Weight (kg) 109.7 (106.3, 146.7) 101.8 (95.4, 118.2)
Adiposity: DEXA and 3-T MRI
BMI (kg/m2) 41.3 (37.7, 47.0) 35.5 (33.2, 43.8)
Total Body Fat (%) 44.8 (38.5, 48.8) 40.6 (34.3, 44.3)
SAAT (L) 11.0 (8.2, 11.7) 9.1 (7.8, 10.9)
VAT (L) 3.4 (2.5, 5.4) 3.3 (2.2, 4.2)
Liver Fat (%) 8.7 (6.2, 13.7) 8.6 (3.4, 12.6)
Pancreatic Fat (%) 6.9 (3.0, 11.8) 5.3 (4.3, 6.7)
2-hr OGTT
Systolic BP (mm/Hg) 122.0 (107.0, 142.0) 114.0 (111.5, 130.0)
Diastolic BP (mm/Hg) 67.0 (63.0, 73.0) 71.0 (68.0, 78.0)
Fasting Glucose (mg/dL) 86.2 (82.9, 95.1) 83.2 (78.7, 86.9)
Fasting Insulin (μU/mL) 11.0 (9.5, 13.5) 7.2 (5.0, 10.2)*
Fasting C-Peptide (ng/mL) 3.6 (2.6, 3.9) 2.9 (2.2, 3.3)
Fasting Insulin / C-peptide 3.3 (3.0, 3.8) 2.8 (2.5, 3.4)*
Fasting FFA (μM/L) 510.7 (395.5, 519.1) 459.2 (376.1, 502.9)
QUICKI 0.34 (0.33, 0.34) 0.36 (0.34, 0.38)*
HOMA-IR 2.2 (2.0, 2.8) 1.5 (1.0, 2.3)*
HOMA-B 157.9 (146.1, 215.3) 142.2 (85.3, 187.0)
Matsuda Index 1.9 (1.4, 2.1) 2.7 (2.0, 3.8)†
Glucose AUC (mg/dL × min) 280.6 (257.9, 317.9) 268.9 (234.6, 285.7)
Insulin AUC (μU/mL × min) 114.8 (92.2, 147.8) 88.0 (70.4, 108.5)
C-Peptide AUC (ng/mL × min) 22.4 (19.3, 26.2) 18.9 (17.9, 23.0)
Plasma Markers
hsIL-6 (pg/mL) 2.6 (1.8, 3.1) 2.4 (1.8, 3.8)
sTNFrII (pg/mL) × 102 23.8 (19.7, 27.8) 22.8 (17.3, 26.0)
sCD14 (ng/mL) × 102 12.7 (11.6, 13.1) 13.1 (11.5, 14.4)
sCD163 (ng/mL) 47.5 (36.6, 61.5) 41.7 (35.4, 70.3)
Adiponectin (ng/mL) × 102 63.6 (52.4, 92.6) 64.5 (48.3, 88.0)
Adipsin (ng/mL) 31.7 (27.1, 35.8) 27.1 (24.7, 34.0)
Adipose Tissue Biopsies
Average Fat Cell Size (μ2) × 102 59.5 (44.6, 72.3) 55.3 (51.8, 62.8)
CLS [Y/N, (%)] 7/4 (64%) 3/10 (23%)
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Salsalate
N=11
Placebo
N=13
Leukocytes (%) 20.9 (8.9, 35.1) 17.5 (9.3, 24.7)
Monocytes/Macrophages (%) 29.0 (15.0, 59.1) 34.0 (25.8, 42.5)
Data are reported as median (25th, 75th percentile). P-value corresponds to Mann-Whitney U Test on Medians.
*
P<0.05 and
†
P≤0.01. Salsalate group: N=10 for MRI. Placebo group: N=12 for flow cytometry.
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